Viewing posts by Claude Walker

Will Tassal (ASX: TGR) boost dividends, or use strong cashflow to boost the business?

Tassal has had a remarkable year. The shareprice increased over 2013 from $1.43 to $3.30, an increase of 130%. Profit after tax and dividends over FY 2013 were up over 18%, despite revenue being flat. This was mainly because of the significant reduction in borrowings. A few years ago borrowings were over 60%, with the funds used to develop the salmon farm at Macquarie Harbour in western Tasmania. At the beginning of FY 2013, borrowings were an already respectable 25% of equity and reduced over the year to 18%.

read more

Introduction to Cryosite (ASX: CTE)

I'll have to keep this note quite short, because I'm writing from Strahan in Tasmania, about to go for a walk to see the local platypus (fingers crossed). Tomorrow we'll be trekking in the Wild Rivers National Park, a place environmentalists fought hard to protect from destruction.

read more

Energy Action downgrades profit guidance (ASX: EAX)

So I thought I should share my thoughts on the recent announcement by Energy Action (ASX: EAX).

read more

Why I'm no longer interested in Codan (ASX: CDA)

Subscribers will know that when Codan announced their original profit downgrade, I took the opportunity to buy shares from panic sellers. At the time, I described the position as a "research position" and subsequently, I did my research. One disturbing piece of information that I found was that the Chinese may have had access to Codan's secure radio codes.

read more

Introduction to Global Health (ASX: GLH)

Today I’m writing about Global Health (ASX: GLH) the smallest company I’ve ever covered on this website.

read more

Checkup on My Net Fone (ASX: MNF)

Just as a follow up to this article, here's a quick note on my recent thoughts about My Net Fone.

read more

Is the Medical Developments investment thesis broken? (ASX: MVP)

Well today I sold my shares in Medical Developments International. It was a borderline call, as the thesis is still mostly there. However, the new piece of information was that the company gave the following guidance:

read more

Hypothetical Ethical Share Portfolio 27 November 2013

Here is the updated hypothetical ethical share portfolio. I'm trying to make my reporting of this hypothetical ethical share portfolio as transparent as possible: suggestions are welcome. I'm thinking of adjusting the buy price to reflect dividends received.

read more

IMF Australia Added to The Hypothetical Ethical Share Portfolio (ASX: IMF)

This is just a short note on IMF Australia (ASX:IMF), [name changing to Bentham IMF] the litigation funders. IMF have recently expanded into the USA, and they had quite low profits in FY 2013. Furthermore, they have just diluted shareholders at a share price of $1.70, and convertible notes are being redeemed at $1.65 per share.

read more

Medical Developments International receives FDA approval for Space Chamber asthma spacers (ASX: MVP)

It has been announced this morning that Medical Developments International has received FDA approval for its Space Chamber asthma spacers. Since I bought shares, the company has moved forward with a number of its initiatives (selling asthma devices into the USA is just one of them). Importantly, the application for marketing approval of Penthrox in Europe has been accepted for consideration. These are both positives. However, the company has also reported reduced sales of Penthrox in Australia, meaning that the shares are no more attractive now than when I bought them, in my opinion. The current price is $1.38 (only slightly above my average entry price).

read more